ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2021 - 2026)

ProQR Therapeutics has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $20.3 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 31.93% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.3 million (down 31.93% YoY) and the FY2025 annual result came in at $24.9 million, down 20.81% from the prior year.
• Non-Current Deffered Revenue eased to $20.3 million in Q1 2026 per PRQR's latest filing, from $24.9 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $69.6 million in Q1 2023 and troughed at $11.4 million in Q3 2022.
• A 5-year average of $36.6 million and a median of $31.4 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deffered Revenue jumped 394.7% in 2023, then slumped 39.92% in 2024.
• Over 5 years, Non-Current Deffered Revenue stood at $66.9 million in 2022, then dropped by 28.96% to $47.5 million in 2023, then tumbled by 33.83% to $31.4 million in 2024, then declined by 20.81% to $24.9 million in 2025, then decreased by 18.64% to $20.3 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $20.3 million, $24.9 million, and $28.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.